Contact Us

Clinical Trials Research Announces Start of New COPD Clinical Trial in Sacramento

Individuals with Severe COPD Encouraged to Inquire About Participation in the Study
    SACRAMENTO, CA, November 16, 2015 /24-7PressRelease/ -- Clinical Trials Research, today announced its participation in a new COPD clinical research study to evaluate the effectiveness and safety of a combination inhaler, tiotropium and olodaterol.

People living with COPD today may have serious COPD exacerbations (flare-ups) that make it very hard to breathe. Exacerbations can result in emergency room visits or overnight stays in the hospital. Exacerbations may also cause your COPD to worsen. Although the medications available today are helpful, some patients may benefit from new investigational drug that can further reduce the number of COPD exacerbations.

"The DYNAGITO COPD clinical trial will enable participants to learn whether the investigational drug combination of Tiotropium and Olodaterol can help them and others living with severe COPD," said Dr. Jeffrey Wayne, Medical Director for Clinical Trials Research. "We encourage people with COPD to contact us to learn more about the DYNAGITO COPD clinical trial."

To participate in the DYNAGITO COPD study, individuals must meet the following criteria:
- Be at least 40 years old.
- Are currently, or have been a smoker.
- Have been told by your doctor that you have severe COPD
- Have had a moderate-to-severe COPD exacerbation (flare-up) in the last year that required treatment with systemic corticosteroids, antibiotics, or hospitalization.

Those who are eligible to participate in the DYNAGITO COPD clinical trial should expect the following:
- The study will last 55 weeks.
- It includes 7 visits to the study site and 4 telephone calls from the study staff.
- Undergo medical exams and have blood taken for laboratory tests.
- Have your breathing (lung function) measured.
- Be shown how to use the inhaler device.

Tiotropium is an inhaled bronchodilator. It is available in more than 100 countries worldwide. It is a prescription medicine for treating COPD. Triotropium has been shown to decrease the number of COPD exacerbations in people with COPD.

Olodaterol is also an inhaled bronchodilator. It is available in more than 30 countries worldwide. It is also a prescription medicine for treating COPD. Olodaterol has been show to improve breathing for people with COPD.

To learn more about eligibility to participate in the DYNAGITO COPD clinical trial, please contact Dr. Wayne at 916-434-8230 or visit http://www.clinicaltrialscopd.com/.

About Clinical Trials Research & Dr. Jeffrey Wayne, MD

Dr. Jeffrey D. Wayne has been conducting medical research Studies in the greater Sacramento area for more than 20 years. Clinical Trials Research has two research facilities; one in Sacramento, and one in Lincoln, California.

Dr. Wayne has participated in more than 100 Clinical trials including indications in: Hypertension, Diabetes, Lipid, Metabolic Syndrome and Obesity, CHF and other Cardiovascular Disease, Bronchitis, Asthma, COPD, Urinary Tract Infections, Dyspepsia, GERD, Diverticulitis, Irritable Bowel Syndrome, Gastric Ulcers, Osteoarthritis, Fibromyalgia, Anxiety, and Womens's Health/Endometrial.

To learn more about current Clinical research studies viit http://www.ctrsites.com

PR and Internet Marketing by Achieve DMA


# # #



Comment on this story...

Share This Story


Email this Story

Contact Information


Dr. Jeffrey Wayne, MD
Clinical Trials Research

Lincoln, CA
USA
Voice: 916-434-8230
E-Mail: Email Us Here
Website: Visit Our Website

Like This Story?


I like it! 0

Disclaimer


If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7 Press Release Newswire. We are unable to assist you with any information regarding this release. 24-7 Press Release Newswire disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.